Thank you, Dr. Kelly. Thank you for having me.

A very kind introduction.

Before we get started, let me just do a quick check of the audience.

Who here's a fellow in the program?

Okay, so your interests are hematology oncology or mostly heath?

They don't want to be careful.

And then who's the faculty?

Okay, some people.

But we're talking hematology and hemolignity of people.

Okay.

All right.

So this is how to read and interpret blood cancer trials.

I took out all the oncology.

So we'll keep it heathed for this. And I guess I should say, what do I do?

So I'm a professor in epidemiology at UCSF, and I attend, I do 14 weeks of service, but I do hemank consuls.

We do everything from von Willebrand to sarcoma at the general and at the VA.

We've got three hospitals. And then I do the heem and he malignancy at the general and at the VA. We've got three hospitals. And then I do

the he and hemingency at the general, our county hospital. And then at VA, I do a clinic

where it's just all come, whatever walks in the door. So I tried to do a little bit of everything.

So in this talk, I don't know, we'll talk a little bit about how to think better about

hemalignancies, crossover, and how blood cancer

drugs are approved. And then we'll go from there. And you can choose your own adventure

...